Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TACTIK: Personalized Treatment of mCRPC Based on CTC Kinetics
NCT03101046Phase 2Completed
- Sponsor
- Unicancer
- Start
- Nov 2018
- Primary completion
- Dec 2021
- Countries
- 1
01
Overview
A Phase 2 trial of cabazitaxel ginsenoside liposome injection in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Unicancer. Started Nov 2018; status: completed.
02
Drugs
cabazitaxel ginsenoside liposome injection
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT03101046.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03101046.